Shares of UK infectious disease specialist Destiny Pharma (AIM: DEST) closed down almost 25% at 36.10 pence on Friday, despite the company announcing a licensing deal that could earn it more that half a billion dollars, albeit heavily back-loaded.
Destiny has signed an exclusive collaboration and co-development agreement for the North American (USA, Canada and Mexico) rights of NTCD-M3, its lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence, with USA-based Sebela Pharmaceuticals, a company with a market-leading position in gastroenterology.
The share price slump was caused by Destiny’s announcement of a share placement, but the deal with Sebela should de-risk the Phase III trial of the drug. The phase III trial will start next year and there could be a commercial launch in 2027 if everything goes to plan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze